- Tyvaso DPI™ (inhaled treprostinil)
-
Therapeutic Platform
Tyvaso®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Pulmonary Hypertension (PH) WHO Group 3Status
Phase 3Dry Powder Inhaled (DPI) treprostinil in a small handheld device for the treatments of pulmonary arterial hypertension (PAH), and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
LEARN MORE Close - PERFECT (inhaled treprostinil)
-
Product
PERFECT
(inhaled treprostinil)Therapeutic Platform
Tyvaso®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 3Status
Phase 3Phase 3 clinical trial with Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD).
LEARN MORE Close - TETON Studies (inhaled treprostinil)
-
Therapeutic Platform
Tyvaso®Targeted Indication
Idiopathic Pulmonary Fibrosis (IPF)Status
Phase 3Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies of the Efficacy and Safety of Inhaled Treprostinil in Patients with Idiopathic Pulmonary Fibrosis (IPF).
LEARN MORE Close - ADVANCE Studies Ralinepag (IP receptor agonist)
-
Therapeutic Platform
NCE / Novel BiologicsTargeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 3An IP receptor agonist that is a next-generation, once-a-day oral therapy that targets the prostacyclin pathway for patients with pulmonary arterial hypertension (PAH).
LEARN MORE Close
Menu